- This largest cohort study of male breast cancer (~16,500 male patients) showed that mastectomy is the most common therapy (90.4%) and is associated with the longest survival.
- The analysis also showed that despite 91.3% of patients being estrogen receptor (ER)-positive, only 54.7% receive hormone therapy.
Why this matters
- Findings suggest that hormone therapy is underused among male patients with breast cancer.
- The incidence of male breast cancer is increasing.
- Retrospective, population-based, national cohort (the US National Cancer Database) of 16,498 male patients with breast cancer (2004-2015).
- Funding: None.
- Median age, 63 years; total follow-up time, 13 years.
- Mastectomy was the most frequent treatment modality (90.4%).
- 5-year Kaplan-Meier survival was 77.7% (95% CI, 76.9%-78.4%); 10-year survival was 60.7% (95% CI, 59.4%-62.0%).
- According to Cox proportional hazards (adjusted for age, comorbidity, and tumor stage, among others), mastectomy was associated with the longest survival (HR, 0.49; P<.001 followed by hormone therapy p chemotherapy and radiation>
- Although 91.3% of the cohort was ER+, only 54.7% of the cohort received hormone therapy.
- Hormone therapy may have been underreported.
- Did not compare results to those of women in the database.
- Observational, retrospective design.